Ginkgo Bioworks Holdings Inc (DNA)
0.4331
-0.02
(-3.69%)
USD |
NYSE |
Jun 17, 13:11
Ginkgo Bioworks Holdings SG&A Expense (Quarterly): 70.29M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 70.29M |
December 31, 2023 | 89.22M |
September 30, 2023 | 82.03M |
June 30, 2023 | 102.34M |
March 31, 2023 | 111.43M |
December 31, 2022 | 121.38M |
September 30, 2022 | 435.22M |
June 30, 2022 | 438.43M |
Date | Value |
---|---|
March 31, 2022 | 434.77M |
December 31, 2021 | 781.63M |
September 30, 2021 | 28.96M |
June 30, 2021 | 34.44M |
March 31, 2021 | 17.93M |
December 31, 2020 | 12.91M |
September 30, 2020 | 9.876M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
9.876M
Minimum
Sep 2020
781.63M
Maximum
Dec 2021
184.72M
Average
89.22M
Median
Dec 2023
SG&A Expense (Quarterly) Benchmarks
Pacific Biosciences of California Inc | 43.75M |
Teladoc Health Inc | 349.39M |
Prime Medicine Inc | 11.16M |
Inovio Pharmaceuticals Inc | 10.57M |
Nektar Therapeutics | 20.15M |